Kathmere Capital Management LLC Has $358,000 Stock Holdings in Cencora, Inc. (NYSE:COR)

Kathmere Capital Management LLC raised its holdings in Cencora, Inc. (NYSE:COR) by 5.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,587 shares of the company’s stock after acquiring an additional 89 shares during the quarter. Kathmere Capital Management LLC’s holdings in Cencora were worth $358,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in COR. Rise Advisors LLC acquired a new stake in shares of Cencora in the first quarter worth $25,000. Legacy Bridge LLC acquired a new stake in shares of Cencora in the first quarter worth $27,000. New Millennium Group LLC acquired a new stake in shares of Cencora in the second quarter worth $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the first quarter worth $29,000. Finally, TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the first quarter worth $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Up 0.5 %

Shares of Cencora stock opened at $224.92 on Friday. The firm has a market capitalization of $44.86 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The company’s fifty day moving average price is $234.96 and its two-hundred day moving average price is $232.73. Cencora, Inc. has a 52-week low of $178.21 and a 52-week high of $247.66.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.92 EPS. On average, analysts expect that Cencora, Inc. will post 13.63 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.91%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The disclosure for this sale can be found here. Insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799 in the last 90 days. 15.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on COR. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Bank of America reiterated a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Leerink Partners reiterated an “outperform” rating and set a $275.00 target price on shares of Cencora in a research note on Thursday, June 27th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average price target of $256.67.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.